md

Osanetant HCl is the (R)-enantiomer; neurokinin-3 receptor antagonist

MD13 是一种巨噬细胞迁移抑制因子 (MIF) 导向的 PROTAC，Ki 值为 71 nM。MD13 可用于癌症研究。

MD-224是一种基于蛋白水解靶向嵌合体（PROTAC）概念的高效、高效的MDM2降解剂，是一类新型抗癌剂。

MD 770222为Cimoxatone的主要血浆O-脱甲基代谢产物，展现出口服活性，且为选择性且可逆的MAO A抑制剂。与Cimoxatone相比，MD 770222的效力较低。

MD-700, 一种新型异苯并呋喃酮，于0.03 microg/ml浓度下能在4小时内提升HepG2细胞中的LDL受体表达。MD-700选择性降低LDL及极低密度脂蛋白胆固醇水平。

MD-265 是一种 PROTAC 降解剂，可降解 MDM2，激活携带野生型 p53 的癌细胞中的 p53，实现肿瘤完全消退，并提高白血病小鼠的长期生存率。

MD-4251 是一种口服的MDM2PROTAC降解剂，能够高效降解 RS4;11 细胞中的MDM2 (DC50：0.2 nM) 并激活p53。它对急性白血病细胞 (野生型 p53) 显示出显著的抗增殖活性，而对突变型细胞的效果不明显。在 RS4;11 异种移植小鼠模型中，MD-4251 可诱导肿瘤完全消退。

Terazosin-md（compound TZ-md）是Alfuzosin和Terazosin的衍生物，作为一种口服活性的α1-肾上腺素能受体（α1-adrenergic receptor）拮抗剂，Terazosin-md 能改善线粒体代谢、降解多种病理性蛋白沉积，并提高血管内皮细胞功能。在阿尔茨海默病小鼠模型中，Terazosin-md 展现了活性，并可应用于阿尔茨海默病及其并发症，以及与蛋白沉积和代谢紊乱相关疾病的研究。

MD 39-AM 的活性通过在含有激动素但不含抗细胞分裂素的培养基上 50% 的愈伤组织生长来评估。

MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice.References1. Kim, S.-H., Hong, S.H., Park, Y.-J., et al. MD001, a novel peroxisome proliferator-activated receptor α/γ agonist, improves glucose and lipid metabolism. Sci. Rep. 9(1), 1656 (2019). MD001 is a dual agonist of peroxisome proliferator-activated receptor α (PPARα) and PPARγ.1 It binds to PPARα and PPARγ (Kds = 9.55 and 0.14 μM, respectively) but does not bind to PPARβ/δ at concentrations up to 500 μM. It increases transcriptional activity of PPARα and PPARγ in a cell-based luciferase reporter assay when used at a concentration of 10 μM. MD001 (10 μM) increases expression of PPARα, PPARγ, and retinoid X receptor (RXR), as well as PPARα and PPARγ target genes, in HepG2 cells. It increases glucose consumption as well as expression of GLUT2 and GLUT4 in HepG2 and 3T3-L1 cells, respectively, in a concentration-dependent manner. MD001 (20 mg/kg) decreases levels of glucose, insulin, free fatty acids, triglycerides, LDL, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in blood and reduces the size and number of hepatic lipid droplets in diabetic db/db mice. References1. Kim, S.-H., Hong, S.H., Park, Y.-J., et al. MD001, a novel peroxisome proliferator-activated receptor α/γ agonist, improves glucose and lipid metabolism. Sci. Rep. 9(1), 1656 (2019).

MD-222, a pioneering, highly potent PROTAC degrader targeting MDM2, efficiently mediates the rapid degradation of MDM2 protein and activates wild-type p53 within cells, showcasing significant anticancer effects[1][2].

MD15 is a negative control for MD13.

MD2-IN-1 是骨髓分化蛋白 2 (MD2) 的抑制剂，对重组人 MD2 (rhMD2) 的 KD 为 189  μM。

MD 780236 is a monoamine oxidase-B inhibitor.

MD 220661 is an inhibitor of semicarbazide-sensitive amine oxidase (SSAO), and a substrate of the enzyme.

MD-230254 is an inhibitor of MAO-B.

MD2-TLR4-IN-1 是一种骨髓分化蛋白 2/toll 样受体 4 (MD2-TLR4) 复合物抑制剂，能够抑制巨噬细胞 LPS 诱导的 TNF-α 和 IL-6 的表达，IC50值分别为 0.89 和 0.53 μM。

MD102是一种高效的Transglutaminase 2抑制剂(IC₅₀≈0.35 μM)，可通过抑制TG2活性调节肿瘤相关信号通路。在细胞模型中，MD102的作用与p53稳定化以及p-AKT和p-mTOR等信号通路下调相关，并可在肿瘤细胞中诱导凋亡。

MDL 101146 is an orally active neutrophil elastase inhibitor.

MD6a 是褪黑素的衍生物，具有抑制多聚ADP核糖聚合酶 (PARP-1) 活性的特性。它通过 TOR/HSF-1 信号通路帮助维持蛋白质稳态，并提升线粒体功能，发挥神经保护的作用。

MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.

2MD是一种口服活性维生素D类似物，能刺激骨膜骨形成并减少小梁骨吸收，从而恢复小梁和皮质骨的质量与强度。在非人灵长类动物研究中，2MD还可以调节(IOP)相关基因，降低眼压。

Anti-Mouse DR5/CD262 Antibody (MD5-1) 是一种来自美国仓鼠的 IgG, κ 型抗体抑制剂，专用于针对小鼠 DR5/CD262。

MD01-67，一种大环化合物，特异性作用于神经降压素 2 型受体 (NTS2)，具有 2.9 nM 的Ki值。在大鼠的急性、持续性及慢性炎症疼痛模型中，MD01-67 展示了显著的镇痛效果和降低触觉过敏的能力。